» Articles » PMID: 25504435

PRK1/PKN1 Controls Migration and Metastasis of Androgen-independent Prostate Cancer Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Dec 16
PMID 25504435
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The major threat in prostate cancer is the occurrence of metastases in androgen-independent tumor stage, for which no causative cure is available. Here we show that metastatic behavior of androgen-independent prostate tumor cells requires the protein-kinase-C-related kinase (PRK1/PKN1) in vitro and in vivo. PRK1 regulates cell migration and gene expression through its kinase activity, but does not affect cell proliferation. Transcriptome and interactome analyses uncover that PRK1 regulates expression of migration-relevant genes by interacting with the scaffold protein sperm-associated antigen 9 (SPAG9/JIP4). SPAG9 and PRK1 colocalize in human cancer tissue and are required for p38-phosphorylation and cell migration. Accordingly, depletion of either ETS domain-containing protein Elk-1 (ELK1), an effector of p38-signalling or p38 depletion hinders cell migration and changes expression of migration-relevant genes as observed upon PRK1-depletion. Importantly, a PRK1 inhibitor prevents metastases in mice, showing that the PRK1-pathway is a promising target to hamper prostate cancer metastases in vivo. Here we describe a novel mechanism controlling the metastatic behavior of PCa cells and identify PRK1 as a promising therapeutic target to treat androgen-independent metastatic prostate cancer.

Citing Articles

Lipid-Binding Regions within PKC-Related Serine/Threonine Protein Kinase N1 (PKN1) Required for Its Regulation.

Lin J, Yuan H Biochemistry. 2024; 63(6):743-753.

PMID: 38441874 PMC: 10956426. DOI: 10.1021/acs.biochem.4c00009.


Upregulation of PKN1 as a Prognosis Biomarker for Endometrial Cancer.

Govorov I, Attarha S, Kovalevska L, Andersson E, Kashuba E, Mints M Cancer Control. 2022; 29:10732748221094797.

PMID: 35533253 PMC: 9092572. DOI: 10.1177/10732748221094797.


The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia.

Edilova M, Law J, Zangiabadi S, Ting K, Mbanwi A, Arruda A Oncoimmunology. 2021; 10(1):1943234.

PMID: 34589290 PMC: 8475556. DOI: 10.1080/2162402X.2021.1943234.


Protein kinase N1 promotes proliferation and invasion of liver cancer.

Wang X, Ge Y, Shi M, Dai H, Liu W, Wang P Exp Ther Med. 2021; 21(6):651.

PMID: 33968181 PMC: 8097187. DOI: 10.3892/etm.2021.10083.


The structure and function of protein kinase C-related kinases (PRKs).

Sophocleous G, Owen D, Mott H Biochem Soc Trans. 2021; 49(1):217-235.

PMID: 33522581 PMC: 7925014. DOI: 10.1042/BST20200466.


References
1.
Hollenhorst P, Ferris M, Hull M, Chae H, Kim S, Graves B . Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 2011; 25(20):2147-57. PMC: 3205585. DOI: 10.1101/gad.17546311. View

2.
Choudhury Y, Yang Z, Ahmad I, Nixon C, Salt I, Leung H . AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience. 2015; 1(6):446-56. PMC: 4284621. DOI: 10.18632/oncoscience.49. View

3.
Metzger E, Muller J, Ferrari S, Buettner R, Schule R . A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J. 2003; 22(2):270-80. PMC: 140098. DOI: 10.1093/emboj/cdg023. View

4.
Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N . MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience. 2015; 1(4):250-261. PMC: 4278297. DOI: 10.18632/oncoscience.30. View

5.
Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X . Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2007; 134(3):365-72. DOI: 10.1007/s00432-007-0292-z. View